InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

Current share price for NEU : $20.210 0.01 (0.05%)+

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,562 Respone to ASX price query 20 Jan 2009 10:07AM $0.012 $20.210 risen by 168,316.67%
$2,562 Trading Halt 19 Jan 2009 10:32AM $0.012 $20.210 risen by 168,316.67%
$2,562 Neuren Announces Glypromate Trial Preliminary Results 24 Dec 2008 8:24AM $0.011 $20.210 risen by 183,627.27%
$2,562 Phase 3 trial data collection completed 10 Nov 2008 9:40AM $0.060 $20.210 risen by 33,583.33%
$2,562 Appendix 4C - quarterly 31 Oct 2008 2:56PM n/a $20.210 n/a
$2,562 US Army to provide additional NNZ2566 trial funding 4 Sep 2008 12:26PM $0.079 $20.210 risen by 25,482.28%
$2,562 Half Yearly Report and Accounts 29 Aug 2008 12:25PM $0.074 $20.210 risen by 27,210.81%
$2,562 Neuren signs cancer license and collaboration agreement 27 Aug 2008 9:05AM $0.079 $20.210 risen by 25,482.28%
$2,562 Neuren raises a minimum of $3 million 6 Aug 2008 10:34AM $0.084 $20.210 risen by 23,959.52%
$2,562 Reinstatement to Official Quotation 6 Aug 2008 10:34AM $0.090 $20.210 risen by 22,355.56%
$2,562 Suspension from Official Quotation 31 Jul 2008 10:02AM n/a $20.210 n/a
$2,562 Trading Halt 29 Jul 2008 10:08AM n/a $20.210 n/a
$2,562 Glypromate and NNZ 2566 in Top 10 Neuroscience Projects 21 Jul 2008 8:59AM $0.130 $20.210 risen by 15,446.15%
$2,562 Neuren to get early results from Glypromate trial 30 Jun 2008 8:32AM $0.110 $20.210 risen by 18,272.73%
$2,562 Response to ASX Query re: Appendix 4C 26 May 2008 5:52PM $0.105 $20.210 risen by 19,147.62%
$2,562 Positive interim safety analysis for Glypromate 15 May 2008 9:09AM $0.110 $20.210 risen by 18,272.73%
$2,562 Appendix 4C - quarterly 30 Apr 2008 3:38PM $0.110 $20.210 risen by 18,272.73%
$2,562 Quarterly Update to Shareholders April 2008 29 Apr 2008 3:28PM $0.105 $20.210 risen by 19,147.62%
$2,562 Appendix 4E Preliminary Final Report 29 Feb 2008 2:27PM $0.120 $20.210 risen by 16,741.67%
$2,562 Rights issue raises $7.1m and notes convert 11 Feb 2008 2:08PM $0.130 $20.210 risen by 15,446.15%
$2,562 Neuren Appendix 4C December 2007 31 Jan 2008 3:54PM $0.150 $20.210 risen by 13,373.33%
$2,562 US Department of Defense Approves NNZ2566 Funding 21 Jan 2008 1:15PM $0.170 $20.210 risen by 11,788.24%
$2,562 Glypromate trial recruits 100th patient 17 Jan 2008 9:32AM $0.145 $20.210 risen by 13,837.93%
$2,562 Rights Issue NZ Investment Statement and Prospectus 19 Dec 2007 5:19PM $0.160 $20.210 risen by 12,531.25%
$2,562 Neuren announces non-renounceable rights issue 19 Dec 2007 10:26AM $0.200 $20.210 risen by 10,005%

751 - 775 of 833 results

Page 31 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.